Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

Organogenesis Holdings Inc.

2024-Q1 EPS reported -$0.02 revenue$109,976,000

Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).
GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.
FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.
Cash $89.3M, debt $64.9M as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $110.0 million
Net income: $2.1 million
EPS: $(0.02) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.